Observation on the Efficacy and Safety of Riociguat in Patients with Chronic Obstructive Pulmonary Disease (COPD) Complicated by Pulmonary Arterial Hypertension (PAH)

Ying Peng

Show Less

¹ Zhongxiang People’s Hospital, Zhongxiang 431900, Hubei, China,

JCNR 2026 , 10(5), 126–134; https://doi.org/10.26689/jcnr.v10i5.15227

© 2026 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Objective: To investigate the efficacy and safety of riociguat in patients with chronic obstructive pulmonary disease (COPD) complicated by pulmonary arterial hypertension (PAH). Methods: A total of 98 patients with COPD and PAH admitted to Zhongxiang People’s Hospital from January 2023 to December 2024 were selected and randomly divided into a control group and an observation group using a random number table method, with 49 patients in each group. The control group received conventional treatment, while the observation group received riociguat in addition to the conventional treatment. Clinical efficacy, pulmonary function indicators, pulmonary artery pressure indicators, blood gas indicators, and 6-minute walking distance were compared between the two groups, and adverse reactions during treatment were recorded. Results: After treatment, the total effective rate in the observation group was 93.88%, higher than that in the control group (79.59%). The pulmonary function indicators, pulmonary artery pressure indicators, blood gas indicators, and 6-minute walking distance in the observation group were superior to those in the control group, with statistically significant differences (p < 0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (p > 0.05). Conclusion: Riociguat treatment can improve pulmonary function, pulmonary artery pressure, and blood gas status in patients with COPD complicated by PAH, enhance exercise tolerance and clinical efficacy, and is safe without increasing the risk of adverse reactions.

References

Olsson K, Corte T, Kamp J, et al., 2023, Pulmonary Hypertension Associated with Lung Disease: New Insights into Pathomechanisms, Diagnosis, and Management. The Lancet Respiratory Medicine, 11(9): 820–835.

Yu X, Cai C, Peng Z, et al., 2025, Research Progress on the Mechanisms of Pulmonary Hypertension in the Acute Exacerbation Stage of Chronic Obstructive Pulmonary Disease Complicated by Cor Pulmonale. Journal of Clinical Pulmonary Medicine, 30(1): 131–137.

Huang A, Pan T, Gao Y, et al., 2025, Changes and Significance of Peripheral Blood NLRP3 Inflammasome Levels in Elderly Patients with Chronic Obstructive Pulmonary Disease Complicated by Pulmonary Hypertension. Geriatrics & Health Care, 31(3): 725–730.

Zhou D, Liu C, Wang L, et al., 2024, Prediction of Clinical Risk Assessment and Survival in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension. Clinical and Translational Medicine, 14(6): e1702.

Peng P, Wang X, Liu M, 2022, Meta-Analysis of Riociguat in Reversing Right Ventricular Remodeling and Improving Right Ventricular Function in Patients with Pulmonary Hypertension. Modern Medicine & Health, 38(12): 2034–2037.

Chinese Medical Association, Chinese Medical Association Journal Editorial Board, Chinese Medical Association General Practice Branch, et al., 2024, China’s Primary Care Guidelines for the Diagnosis and Management of Chronic Obstructive Pulmonary Disease (2024 Edition). Chinese Journal of General Practitioners, 23(6): 578–602.

Pulmonary Embolism and Pulmonary Vascular Disease Group of the Respiratory Disease Branch of the Chinese Medical Association, Pulmonary Embolism and Pulmonary Vascular Disease Working Committee of the Respiratory Physicians Branch of the Chinese Medical Doctor Association, National Pulmonary Embolism and Pulmonary Vascular Disease Prevention and Treatment Collaboration Group, et al., 2021, China’s Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (2021 Edition). Chinese Medical Journal, 101(1): 11–51.

Liu H, Chen D, Zeng Z, 2024, Observation on the Therapeutic Effect of Bufei Yishen Decoction Combined with Respiratory Muscle Function Exercise in Elderly Patients with Chronic Obstructive Pulmonary Disease Complicated by Pulmonary Hypertension. Shanghai Medical & Pharmaceutical Journal, 45(9): 48–52.

Wan Y, Kuang W, Chen X, et al., 2024, Correlation Between Serum Interleukins and Pulmonary Artery Pressure in Patients with Chronic Obstructive Pulmonary Disease Complicated by Pulmonary Hypertension. China Contemporary Medicine, 31(2): 26–29.

Ke Y, Wang W, Men P, et al., 2021, Rapid Health Technology Assessment of the Effectiveness, Safety, and Cost-Effectiveness of Riociguat for the Treatment of Pulmonary Hypertension. Chinese Journal of Hospital Pharmacy, 41(20): 2105–2112.

Li H, Sun F, Yuan P, et al., 2024, Effects of Balloon Pulmonary Angioplasty on Nocturnal Hypoxemia in Patients with Inoperable Chronic Thromboembolic Pulmonary Hypertension. Journal of Tongji University (Medical Edition), 45(5): 641–648.

Cheng J, Sun C, Xue Y, 2020, Observation on the Clinical Efficacy of Riociguat Combined with Sildenafil in the Treatment of Congenital Heart Disease Complicated by Pulmonary Hypertension. Modern Medicine, 48(4): 512–515.

Zhang Q, 2023, Meta-Analysis of Riociguat for the Treatment of Pulmonary Hypertension, thesis, Huazhong University of Science and Technology.

Chang Z, 2021, Study on the Effects of Riociguat on Pulmonary Vascular Remodeling and Right Ventricular Hypertrophy in Shunt-Type Pulmonary Hypertension, thesis, Shandong University.

Chen H, Li Y, Wang Q, et al., 2024, Clinical Efficacy of Ginkgo Biloba Extract Combined with Alprostadil in Patients with Chronic Obstructive Pulmonary Disease Complicated by Pulmonary Hypertension. Chinese Traditional Patent Medicine, 46(9): 2963–2967.

Wei K, 2021, Analysis of the Efficacy and Safety of Riociguat Combined with Sildenafil in the Treatment of Pulmonary Hypertension After Congenital Heart Disease Surgery. Clinical Medical Engineering, 28(9): 1249–1250.

Previous article in this issue

Next article in this issue